Survival in Idiopathic Inflammatory Myopathies and Associated Factors
Keywords:
polymyositis; dermatomyositis; survivalAbstract
Introduction: Idiopathic inflammatory myopathies are systemic and autoimmune diseases, characterized by proximal weakness, and are classified into dermatomyositis and polymyositis.
Objetive: To estimate the survival of patients with idiopathic inflammatory myopathies.
Methods: With an observational, longitudinal, and retrospective study was conducted in the Rheumatology Service of the Clinical Surgical Hospital Hermanos Ameijeiras in the period between april 2005 and july 2020. The sample was done with 104 patients diagnosed with adult-onset myocardial infarction who attended the standardized clinic protocol that fulfilled the selection criteria. Demographic, clinical, and morbidity/mortality variables were collected.
Results: 83,7 % were female. The delay time to diagnose polymyositis of was 15 months, and for dermatomyositis was 8 months. The average age of those who died was 53 years. Deaths were more frequent in the first four years and were related to disease activity.
Conclusions: Females, whites, urban residents, and those with dermatomyositis predominated. Survival curves showed higher mortality rates for polymyositis and active disease. The presence of neoplasia in dermatomyositis increased the risk of death 35 times compared to those without neoplasia. The causes of death were cardiovascular, neoplastic, and infectious.
Downloads
References
1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-7. DOI: https://doi.org/10.1056/NEJM197502132920706
2. Tanboon J, Nishino I. Classification of idiopathic inflammatory myopathies: pathology perspectives. Curr Opin Neurol. 2019;32(5):704-14. DOI: https://doi.org/10.1097/WCO.000000000000074
3. Tanboon J, Uruha A, Stenzel W, Nishino I. Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol. 2020;33(5):590-603. DOI: https://doi.org/10.1097/WCO.000000000000085
4. Argüelles Zayas A, Chico Capote A, Kokuina E, Casas Figueredo N. Características clínicas, inmunológicas y daño de órganos en pacientes con miopatías inflamatorias idiopáticas. Rev Cuban Med. 2021 [acceso 14/10/2025];60(2):e1345. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttex&pid=S0034-75232014000400003
5. Acosta I, Matamala JM, Jara P, Pino F, Gallardo A, Verdugo R. Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo. Rev Med Chil. 2019;147(3):342-55. DOI: https://doi.org/10.4067/S0034-98872019000300342.
6. Cobo Ibáñez T. Mora Ortega GM. Enfermedad pulmonar intersticial difusa en las miopatías inflamatorias idiopáticas. Rev Patol Respir. 2019 [acceso 12/02/2020];22(Supl.1):S139-40. Disponible en: https://www.revistadepatologiarespiratoria.org/descargas/PR_22-S1_S139-S140.pdf
7. Iturburu Al. Nuevos conceptos del Síndrome Antisintetasa. [Tesis]. Espaňa׃ Universitat Autonoma de Barcelona; 2013 [acceso 12/02/2020]. Disponible en: https://www.tdx.cat/bitstream/10803/129321/1/alir1de1.pdf
8. González MR. Miopatías inflamatorias idiopáticas. Rev Clin Esp. 2002 [acceso 12/02/2020];202:500-8. Disponible en: https://www.tdx.cat/bitstream/10803/129321/1/alir1de1.pdf
9. Inoue M, Tanboon J, Hirakawa S. Association of dermatomyositissinedermatitis and with anti-nuclear matrix protein 2 autoantibodies. JAMA Neurol. 2020;77:1-6. DOI: https://doi.org/10.1001/jamaneurol.2020.0673
10. Fujisawa T. Management of myositis associated interstitial lung disease. Medicina (Kaunas). 2021;57(4):347. DOI: https://doi.org/10.3390/medicina57040347
11. Ponce YM, Zalazar MM, García Coello AD, Rillo OL. Serie de casos clínicos de pacientes con Miopatía inflamatoriaidiopática y enfermedad pulmonar intersticial del registro de miopatías inflamatorias idiopáticas de la Sociedad Argentinade Reumatología. Rev Argent Reumatol. 2020 [acceso 12/02/2020];31(1)12-7. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/422
12. World Medical Assocition Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):1-95. DOI: https://doi.org/10.1001/jama.2013.281053
13. Nuño-Nuño L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Cubas IL, et al. Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatol Int. 2017;37(11):1853-61. DOI: https://doi.org/10.1007/s00296-017-3799-x.
14. Galindo-Feria AS, Rojas-Serrano J, Hinojosa-Azaola A. Clinical and prognostic factors associated with survival in Mexican patients with idiopathic inflammatory myopathies. J Clin Rheumatol. 2016;22(2):51-6. DOI: https://doi.org/10.1097/RHU.0000000000000365
15. Amaral Silva M, Cogollo E, Isenberg DA. Why do patients with myositis die? A retrospective analysis of a single-centre cohort. Clin Exp Rheumatol. 2016 [acceso 12/02/2020];34(5):820-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27494511/
16. András C, Bodoki L, Nagy-Vincze M, Griger Z, Csiki E, Dankó K. Retrospective analysis of cancer-associated myositis patients over the past 3 decades in a Hungarian myositis cohort. Pathol Oncol Res. 2020;26(3):1749-55. DOI: https://doi.org/10.1007/s12253-019-00756-4
17. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc HealthRisk Manag. 2008;4(3):605-14. DOI: https://doi.org/10.2147/vhrm.s2453.
18. Vonk MC, Vandecasteele E, van Dijk AP. Pulmonaryhypertension in connective tissue diseases, new evidence and challenges. Eur J Clin Invest. 2021;51(4):e13453. DOI: https://doi.org/10.1111/eci.13453
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ana del Carmen Argüelles Zayas, Ángel Chacón Caveros, Araceli Chico Capote, Adalberto Luis Infante Amorós , Nelsa Casas Figueredo, Miguel Hernán Estévez del Toro Estévez del Toro
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
